{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T20:24:21Z","timestamp":1780604661195,"version":"3.54.1"},"reference-count":33,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100014088","name":"AstraZeneca France","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014088","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Archives of Cardiovascular Diseases"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.acvd.2021.06.003","type":"journal-article","created":{"date-parts":[[2021,7,15]],"date-time":"2021-07-15T10:14:17Z","timestamp":1626344057000},"page":"612-623","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Is platelet function testing at the acute phase under P2Y12 inhibitors helpful in predicting bleeding in real-life patients with acute coronary syndrome? The AVALANCHE study"],"prefix":"10.1016","volume":"114","author":[{"given":"Claire","family":"Bal dit Sollier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natacha","family":"Berge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Hamadouche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2413-4164","authenticated-orcid":false,"given":"Caren","family":"Brumpt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2942-0901","authenticated-orcid":false,"given":"Alain","family":"Stepanian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Henry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginie","family":"Siguret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6123-9694","authenticated-orcid":false,"given":"Ludovic","family":"Drouet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0604-1976","authenticated-orcid":false,"given":"Jean-Guillaume","family":"Dillinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.acvd.2021.06.003_bib0170","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1093\/eurheartj\/ehx393","volume":"39","author":"Ibanez","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.acvd.2021.06.003_bib0175","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1161\/CIR.0000000000000336","volume":"133","author":"Levine","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.acvd.2021.06.003_bib0180","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.acvd.2021.06.003_bib0185","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","article-title":"Prasugrel versus clopidogrel in patients with acute coronary syndromes","volume":"357","author":"Wiviott","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.acvd.2021.06.003_bib0190","doi-asserted-by":"crossref","first-page":"105","DOI":"10.14740\/cr560w","article-title":"Comparison of Clopidogrel With Prasugrel and Ticagrelor in Patients With Acute Coronary Syndrome: Clinical Outcomes From the National Cardiovascular Database ACTION Registry","volume":"8","author":"Khayata","year":"2017","journal-title":"Cardiol Res"},{"key":"10.1016\/j.acvd.2021.06.003_bib0195","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1093\/ehjcvp\/pvw005","article-title":"P2Y12 receptor inhibitors in patients with non-ST-elevation acute coronary syndrome in the real world: use, patient selection, and outcomes from contemporary European registries","volume":"2","author":"Zeymer","year":"2016","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"10.1016\/j.acvd.2021.06.003_bib0200","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.thromres.2016.05.002","article-title":"High platelet reactivity on aspirin in patients with acute ST elevation myocardial infarction","volume":"144","author":"Dillinger","year":"2016","journal-title":"Thromb Res"},{"key":"10.1016\/j.acvd.2021.06.003_bib0205","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/S0735-1097(02)03014-0","article-title":"A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease","volume":"41","author":"Gum","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.acvd.2021.06.003_bib0210","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1016\/j.jacc.2013.07.101","article-title":"Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding","volume":"62","author":"Tantry","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.acvd.2021.06.003_bib0215","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1080\/09537104.2018.1478404","article-title":"Equilibrative nucleoside transporter 1 gene polymorphisms and clinical outcomes following acute coronary syndromes: findings from the PLATelet inhibition and patient Outcomes (PLATO) study","volume":"30","author":"Parker","year":"2019","journal-title":"Platelets"},{"key":"10.1016\/j.acvd.2021.06.003_bib0220","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.jacc.2013.09.067","article-title":"Ticagrelor increases adenosine plasma concentration in patients with an acute coronary syndrome","volume":"63","author":"Bonello","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.acvd.2021.06.003_bib0225","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.ijcard.2014.07.019","article-title":"Ticagrelor effectiveness overestimated by VASP index: platelet inhibition by ticagrelor versus prasugrel in acute coronary syndrome patients according to platelet function tests","volume":"176","author":"Dillinger","year":"2014","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.acvd.2021.06.003_bib0230","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.acvd.2015.04.004","article-title":"Platelet effect of prasugrel and ticagrelor in patients with ST-segment elevation myocardial infarction","volume":"108","author":"Kerneis","year":"2015","journal-title":"Arch Cardiovasc Dis"},{"key":"10.1016\/j.acvd.2021.06.003_bib0235","doi-asserted-by":"crossref","first-page":"570","DOI":"10.3109\/09537104.2014.959914","article-title":"COMparison of Platelet reactivity following prAsugrel and ticagrelor loading dose in ST-Segment elevation myocardial infarctION patients: The COMPASSION study","volume":"26","author":"Laine","year":"2015","journal-title":"Platelets"},{"key":"10.1016\/j.acvd.2021.06.003_bib0240","doi-asserted-by":"crossref","first-page":"3070","DOI":"10.1093\/eurheartj\/ehx175","article-title":"Benefit of switching dual antiplatelet therapy after acute coronary syndrome: the TOPIC (timing of platelet inhibition after acute coronary syndrome) randomized study","volume":"38","author":"Cuisset","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.acvd.2021.06.003_bib0245","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1016\/S0140-6736(17)32155-4","article-title":"Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial","volume":"390","author":"Sibbing","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.acvd.2021.06.003_bib0250","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1093\/eurheartj\/ehy394","article-title":"2018 ESC\/EACTS Guidelines on myocardial revascularization","volume":"40","author":"Neumann","year":"2019","journal-title":"Eur Heart J"},{"key":"10.1016\/j.acvd.2021.06.003_bib0255","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1161\/CIRCULATIONAHA.110.009449","article-title":"Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium","volume":"123","author":"Mehran","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.acvd.2021.06.003_bib0260","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0735-1097(88)90158-1","article-title":"Thrombolysis in Myocardial Infarction (TIMI) Trial--phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase","volume":"11","author":"Rao","year":"1988","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.acvd.2021.06.003_bib0265","doi-asserted-by":"crossref","first-page":"2933","DOI":"10.1093\/eurheartj\/ehr422","article-title":"Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trial","volume":"32","author":"Becker","year":"2011","journal-title":"Eur Heart J"},{"key":"10.1016\/j.acvd.2021.06.003_bib0270","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1093\/eurheartj\/ehv320","volume":"37","author":"Roffi","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.acvd.2021.06.003_bib0275","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/j.jacc.2006.04.090","volume":"48","author":"Montalescot","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.acvd.2021.06.003_bib0280","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1038\/194927b0","article-title":"Aggregation of blood platelets by adenosine diphosphate and its reversal","volume":"194","author":"Born","year":"1962","journal-title":"Nature"},{"key":"10.1016\/j.acvd.2021.06.003_bib0285","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1111\/joic.12076","article-title":"Monitoring persistent platelet reactivity in patients with unprotected left main stenting","volume":"26","author":"Dillinger","year":"2013","journal-title":"J Interv Cardiol"},{"key":"10.1016\/j.acvd.2021.06.003_bib0290","doi-asserted-by":"crossref","DOI":"10.1016\/j.ahj.2012.06.008","article-title":"Biological efficacy of twice daily aspirin in type 2 diabetic patients with coronary artery disease","volume":"164","author":"Dillinger","year":"2012","journal-title":"Am Heart J"},{"key":"10.1016\/j.acvd.2021.06.003_bib0295","first-page":"627","article-title":"Receiver Operating Characteristic (ROC) Curve Analysis for Medical Diagnostic Test Evaluation","volume":"4","author":"Hajian-Tilaki","year":"2013","journal-title":"Caspian J Intern Med"},{"key":"10.1016\/j.acvd.2021.06.003_bib0300","doi-asserted-by":"crossref","first-page":"2877","DOI":"10.1093\/eurheartj\/ehn419","article-title":"Comparison of four tests to assess inhibition of platelet function by clopidogrel in stable coronary artery disease patients","volume":"29","author":"Lordkipanidze","year":"2008","journal-title":"Eur Heart J"},{"key":"10.1016\/j.acvd.2021.06.003_bib0305","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1111\/j.1538-7836.2012.04875.x","article-title":"Relationship between post-treatment platelet reactivity and ischemic and bleeding events at 1-year follow-up in patients receiving prasugrel","volume":"10","author":"Bonello","year":"2012","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.acvd.2021.06.003_bib0310","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/j.jcin.2013.04.009","article-title":"Clinical implications of very low on-treatment platelet reactivity in patients treated with thienopyridine: the POBA study (predictor of bleedings with antiplatelet drugs)","volume":"6","author":"Cuisset","year":"2013","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.acvd.2021.06.003_bib0315","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1001\/jama.2011.290","article-title":"Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial","volume":"305","author":"Price","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.acvd.2021.06.003_bib0320","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1016\/S0140-6736(16)31323-X","article-title":"Platelet function monitoring to adjust antiplatelet therapy in elderly patients stented for an acute coronary syndrome (ANTARCTIC): an open-label, blinded-endpoint, randomised controlled superiority trial","volume":"388","author":"Cayla","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.acvd.2021.06.003_bib0325","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1016\/j.jacc.2012.02.026","volume":"59","author":"Trenk","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.acvd.2021.06.003_bib0330","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1007\/s00228-015-1917-9","article-title":"Genetic and platelet function testing of antiplatelet therapy for percutaneous coronary intervention: the ARCTIC-GENE study","volume":"71","author":"Collet","year":"2015","journal-title":"Eur J Clin Pharmacol"}],"container-title":["Archives of Cardiovascular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1875213621001108?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1875213621001108?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T13:46:59Z","timestamp":1761745619000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1875213621001108"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":33,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["S1875213621001108"],"URL":"https:\/\/doi.org\/10.1016\/j.acvd.2021.06.003","relation":{},"ISSN":["1875-2136"],"issn-type":[{"value":"1875-2136","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Is platelet function testing at the acute phase under P2Y12 inhibitors helpful in predicting bleeding in real-life patients with acute coronary syndrome? The AVALANCHE study","name":"articletitle","label":"Article Title"},{"value":"Archives of Cardiovascular Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.acvd.2021.06.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Masson SAS.","name":"copyright","label":"Copyright"}]}}